Abstract 1533P
Background
A T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) inhibitor + an anti-PD-1 antibody is a promising combination which shows potent efficacy in solid tumors. AdvanTIG-105 (NCT04047862) is a phase I/1b open-label study designed to assess the safety and preliminary antitumor activity of anti-TIGIT mAb OCI + anti-PD-1 mAb TIS in pts with metastatic unresectable solid tumors. OCI + TIS was well tolerated in the dose-escalation part, preliminary efficacy was observed, and the recommended phase II dose (RP2D) of OCI 900 mg IV Q3W + TIS 200 mg IV Q3W was established. Here we report results from dose-expansion cohorts 6 (C6) and 7 (C7).
Methods
Treatment-naïve adult pts with histologically/cytologically confirmed metastatic ESCC (C6) or EAC (C7) were enrolled. Pts received the RP2D of OCI + TIS with cisplatin + 5-fluorouracil/paclitaxel until disease progression, intolerable toxicity, or consent withdrawal. Primary endpoint: investigator-assessed ORR per RECIST v1.1. Secondary endpoints: efficacy (PFS, DoR, DCR), safety and PD-L1 and TIGIT expression as predictive efficacy biomarkers.
Results
As of Feb 2, 2023, 27 pts (C6: n=21; C7: n=6) with a median age of 63.0 y (range C6: 51-72; C7: 58-69) were enrolled; 24 (C6: n=19; C7: n=5) were efficacy evaluable. Efficacy and safety data are summarized in the table. ORRs by biomarker subgroups: C6, 100% in pts with PD-L1 tumor area positivity (TAP) score ≥10% (n=4) vs 76.9% in pts with PD-L1 TAP <10% (n=13); 80.0% in pts with TIGIT IC score ≥5% (n=10) vs 87.5% in pts with TIGIT IC <5% (n=8). C7 had too few pts for biomarker subgroup analysis.
Table: 1533P
Efficacy and Safety Summary
Efficacy Evaluable Set | ||
C6 | C7 | |
Parameter | n=19 | n=5 |
% (95% CI) | ||
ORR | 84.2 (60.4-96.6) | 80.0 (28.4-99.5) |
DCR | 94.7 (74.0-99.9) | 100 (47.8-100) |
mo (95% CI) | ||
Median DoR | 6.7 (4.7-NE) | 3.4 (1.7-NE) |
Median PFS | 8.1 (6.5-NE) | 6.2 (3.0-NE) |
Safety Set | ||
Parameter | n=21 | n=6 |
Median study follow-up (range), wks | 36.1 (1.7-77.0) | 29.3 (8.6-57.1) |
n (%) | ||
Pts with ≥1 TEAE | 21 (100) | 6 (100) |
Grade ≥3 | 14 (66.7) | 6 (100) |
Serious | 9 (42.9) | 4 (66.7) |
imAE | 11 (52.4) | 2 (33.3) |
DCR, disease control rate; DoR, duration of response; imAE, immune-mediate adverse event; mo, months; NE, not estimable; ORR, objective response rate; PFS, progression-free survival; TEAE, treatment-emergent adverse event.
Conclusions
These results demonstrate that OCI 900 mg + TIS 200 mg + CT had a safety profile consistent with previous reports and showed encouraging antitumor activity in pts with stage IV ESCC and EAC.
Clinical trial identification
NCT04047862.
Editorial acknowledgement
Medical writing support, under the direction of the authors, was provided by Apurva Davé, PhD, of MedicalExpressions, an Inizio company, and was funded by BeiGene, Ltd.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
D.R. Spigel: Financial Interests, Personal, Research Funding: AbbVie, Aeglea Biotherapeutics, Agios, Amgen, AnHeart Therapeutics, Apollomics, Arcus, Arrys Therapeutics, Ascendis Pharma, Astellas, AstraZeneca, Bayer, BeiGene, BIND Therapeutics, BioNTech RNA Pharmaceuticals, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Calithera, Celgene, Celldex, Clovis, Cyteir Therapeutics, Daiichi Sankyo, Denovo Biopharma, Eisai, Elevation Oncology, Endeavor, Erasca, Faeth Therapeutics, FujiFilm Pharmaceuticals, G1 Therapeutics, Roche/Genentech, Gilead Sciences, GSK, GRAIL, Hutchison medipharma, ImClone Systems, Incyte, Ipsen, Janssen, Jazz Pharmaceuticals, Kronos Bio, Lilly, Loxo Oncology, Lyell Immunopharma, MacroGenics, MedImmune, Merck, Millennium Pharmaceuticals, Moderna, Molecular Template, Monte Rosa Therapeutics, Nektar, Neon Therapeutics, Novartis, Novocure, Peloton Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Rgenix, Seagen, Shenzhen Chipscreen Biosciences, Stemline Therapeutics, Synthekine, Taiho, Tango Therapeutics, Tarveda, Tesaro, Tizona Therapeutics, Transgene, UT Southwestern, Verastem, Zai Laboratory; Financial Interests, Personal, Advisory Role: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Evidera, GSK, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, Lilly, Molecular Templates, Monte Rosa Therapeutics, Novartis, Novocure, Pfizer, Regeneron Pharmaceuticals, Roche/Genentech, Sanofi-Aventis. H.H. Yoon: Financial Interests, Personal, Speaker, Consultant, Advisor: ALX Oncology, AstraZeneca, BeiGene, Bristol Myer Squibb, MacroGenics, Merck, OncXerna, Zymeworks, Novartis, Amgen; Financial Interests, Personal, Expert Testimony: MJH Life Sciences; Financial Interests, Personal, Other, Honoraria: MJH Life Sciences, Elevation Oncology, Astellas; Financial Interests, Personal, Other, travel, accommodations expenses: BeiGene, Elevation Oncology, Prime, Astellas; Financial Interests, Personal, Research Funding: Merck, Amgen, Bristol Myer Squibb, CARsgen Therapeutics. E.S. Ahern: Financial Interests, Personal, Research Funding: Amgen. H. Zheng; W. Tan; Z. Zhou; Financial Interests, Personal, Full or part-time Employment: BeiGene (Shanghai) Co., Ltd. R. Wang: Financial Interests, Personal, Full or part-time Employment: BeiGene (Shanghai) Co., Ltd; Financial Interests, Personal, Ownership Interest: BeiGene (Shanghai) Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21